Key result
Evolocumab plus atorvastatin linked to ~4-point lower depression scores vs atorvastatin alone in PSD.
Why the study?
PCSK9 may be involved in neuroinflammation and mood regulation, and although evolocumab may have effects beyond lipid lowering when added to statin therapy, its association with depressive symptoms in patients with post-stroke depression remains unclear.
Does evolocumab added to atorvastatin reduce serum PCSK9 concentrations and improve depressive symptoms (HAMD-17 scores) compared to atorvastatin monotherapy in patients with post-stroke depression?
Observational (n=128)
None (non-randomized sequential assignment)
No
Does evolocumab added to atorvastatin reduce serum PCSK9 concentrations and improve depressive symptoms (HAMD-17 scores) compared to atorvastatin monotherapy in patients with post-stroke depression?
Answers are grounded in this paper and cite their sources.
In patients with post-stroke depression, adding evolocumab to atorvastatin was associated with greater reductions in depressive symptoms, inflammatory cytokines, and serum PCSK9 levels over 12 weeks compared to atorvastatin alone, with PCSK9 levels positively correlating with depression severity.
BACKGROUND Post-stroke depression (PSD) is a common neuropsychiatric complication affecting an estimated 30%-40% of stroke survivors and adversely affecting rehabilitation and quality of life. Emerging evidence suggests that proprotein convertase subtilisin/kexin type 9 (PCSK9) may be involved in neuroinflammation and mood regulation. Evolocumab, a PCSK9 inhibitor, may have effects beyond lipid lowering when added to statin therapy; however, its association with depressive symptoms in patients with PSD remains unclear. AIM To investigate the association between serum PCSK9 levels and depression severity in patients with PSD receiving evolocumab plus statin therapy and to assess the association of this combination with changes in depressive symptoms. METHODS This retrospective study included 128 patients with PSD: 64 received evolocumab (140 mg every 2 weeks) plus atorvastatin (20 mg daily), and 64 received atorvastatin alone (20 mg daily). The primary outcomes were serum PCSK9 concentrations and 17-item Hamilton Depression Rating Scale (HAMD-17) scores at baseline and at weeks 4, 8, and 12. Secondary outcomes included Hamilton Anxiety Scale (HAMA) scores, lipid profiles, inflammatory markers [interleukin-6 (IL-6), tumor necrosis factor-α, and high-sensitivity C-reactive protein], and cognitive function assessed using the Montreal Cognitive Assessment (MoCA). Correlation analyses examined associations between PCSK9 concentrations and clinical outcomes. RESULTS At week 12, serum PCSK9 levels decreased from 385.6 ± 78.4 ng/mL to 156.3 ± 42.1 ng/mL in the combination-therapy group, compared with 378.2 ± 76.9 ng/mL to 298.5 ± 68.7 ng/mL in the atorvastatin-only group (P < 0.001). HAMD-17 scores decreased from 22.8 ± 4.5 to 10.2 ± 3.1 and from 22.3 ± 4.2 to 14.6 ± 3.8, respectively (P < 0.001 for the between-group comparison at week 12). Serum PCSK9 levels were positively correlated with HAMD-17 scores at week 12 (r = 0.652, P < 0.001). Compared with the atorvastatin-only group, the combination-therapy group had lower week-12 HAMA scores (8.5 ± 2.3 vs 12.1 ± 3.2, P < 0.001) and IL-6 concentrations (3.2 ± 0.8 pg/mL vs 5.1 ± 1.2 pg/mL, P < 0.001), higher MoCA scores (25.8 ± 2.1 vs 23.4 ± 2.6, P = 0.001), and a higher depression treatment response rate (73.4% vs 48.4%, P = 0.003). CONCLUSION In this retrospective, evolocumab added to atorvastatin was associated with greater reductions in serum PCSK9 levels and depressive symptom scores than atorvastatin alone. The correlation between PCSK9 concentrations and depression severity suggests that PCSK9 warrants further investigation as a potential biomarker in PSD. Prospective studies are needed to establish whether PCSK9 inhibition improves depressive symptoms.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) conducted an observational in Post-stroke depression (PSD) (n=128). Evolocumab plus atorvastatin vs. Atorvastatin 20 mg orally once daily monotherapy was evaluated on 17-item Hamilton Depression Rating Scale (HAMD-17) score and serum PCSK9 levels at 12 weeks (r = 0.652 (correlation between PCSK9 and HAMD-17 at 12 weeks), p=<0.001). Evolocumab plus atorvastatin reduced 12-week HAMD-17 depression scores and serum PCSK9 levels vs atorvastatin alone in PSD.
Synapse has enriched 10 related papers. Consider them for comparative context: